Patent · US Active

Amylin analogues

US10071140B2 · kind B2 · utility

5Cited by

7References

41Claims

0Family size

Assignee

Zealand Pharma A/S · DK

Inventors

Jesper Mosolff MATHIESEN · Farum, DK
Jesper Skodborg VILLADSEN · Skovlunde, DK
Lise GIEHM · Copenhagen, DK
Henrik Kofoed Munch · Copenhagen, DK
Dieter Hamprecht · Verona, IT
Alexander Heim-Riether · Ingelheim am Rhein, DE
Giacomo Fossati · Lissone, IT

Key dates

Filing date	Sep 8, 2017
Grant date	Sep 11, 2018
Priority date	—
Expiry date	Sep 8, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/575
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.